Machida, A.; Oishi, A.; Ikeda, J.; Kurihara, J.; Yoneda, A.; Tsuiki, E.; Hirata, Y.; Murakami, R.; Kitaoka, T. Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept. Life2024, 14, 476.
Machida, A.; Oishi, A.; Ikeda, J.; Kurihara, J.; Yoneda, A.; Tsuiki, E.; Hirata, Y.; Murakami, R.; Kitaoka, T. Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept. Life 2024, 14, 476.
Machida, A.; Oishi, A.; Ikeda, J.; Kurihara, J.; Yoneda, A.; Tsuiki, E.; Hirata, Y.; Murakami, R.; Kitaoka, T. Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept. Life2024, 14, 476.
Machida, A.; Oishi, A.; Ikeda, J.; Kurihara, J.; Yoneda, A.; Tsuiki, E.; Hirata, Y.; Murakami, R.; Kitaoka, T. Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept. Life 2024, 14, 476.
Abstract
To investigate factors associated with the success of switching to faricimab for type 1 macular neovascularization (MNV) refractory to intravitreal aflibercept (IVA). This retrospective cohort study included patients with type 1 MNV who were switched to faricimab because they were refractory to IVA at two centers. The main outcome was an extension of the treatment interval after 6 months, and factors related to the success or failure of the extension and visual and anatomical outcomes were assessed. The analysis included 43 eyes of 43 patients. Extended dosing intervals of more than 2 weeks were identified in 14 eyes (32.6%). A short dosing interval before the switch, the absence of polypoidal lesions, and a thin central choroidal thickness before the switch were identified as factors involved in successful extension. For patients with refractory type 1 MNV, switching to faricimab is a safe and potential option to extend from existing dosing intervals.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.